Lesion impacts on long-term outcomes in patients implanted with bioresorbable vascular scaffold

被引:2
作者
Wang, Yi-Chih [1 ]
Kao, Hsien-Li [1 ]
Wu, Cho-Kai [1 ]
Lin, Mao -Shin [1 ]
Chiang, Fu -Tien [1 ]
Hwang, Juey-Jen [1 ,2 ]
机构
[1] Natl Taiwan Univ Hosp, Dept Internal Med, Cardiovasc Div, Taipei, Taiwan
[2] Natl Taiwan Univ Hosp, Dept Internal Med, Cardiovasc Div, 7 Chung-Shan South Rd, Taipei 100, Taiwan
关键词
Bioresorbable vascular scaffold; Long-term outcome; Lesion complexity; ACC; AHA lesion Classification; PERCUTANEOUS CORONARY; STENT; ABSORB;
D O I
10.1016/j.jfma.2021.10.012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Bioresorbable vascular scaffold (BVS) had been implanted to several kinds of complex coronary lesions in real-world practice. We tested if long-term outcomes of BVS for complex lesions would be worse than that for relatively simple lesions. Methods: We analyzed 457 patients (59 +/- 12 years, 87% male) with 714 BVS implanted for their 529 lesions and median follow-up of 32.7 (26.8-39.3) months. Complex group (N = 284) was defined as those with BVS for acute coronary syndrome, chronic total occlusion, bifurcation/ ostial lesions, instent restenosis/hybrid with metallic stents, diffuse lesions (overlapped by 2 BVS with each S 18 mm), venous graft/left main lesions, or lesions after rotablation. We compared their outcomes with the remaining 173 patients as non-complex group. Results: The complex group had more chronic kidney disease (7% vs. 2%), multivessel disease (78% vs. 65%), use of intravascular imaging (40% vs. 23%), and more BVS (1.8 +/- 0.9 vs. 1.1 +/- 0.3) with longer total lengths (47 +/- 22 vs. 29 +/- 8 mm) implanted than non-complex group (all p < 0.05). However, the long-term target lesion revascularization (TLR) or target lesion failure (TLF) was similar (log rank p > 0.05) between the two groups. Multivariate Cox regression analyses showed BVS for ACC/AHA type C lesions was independently associated with higher risks of TLR (hazard ratio: 2.7, 95% CI = 1.1-6.6) and TLF (hazard ratio: 2.6, 95% CI = 1.1-6.3). Conclusion: Comparable outcomes were found between BVS for complex and non-complex lesion category. However, higher risks of TLR and TLF for type C lesions still suggested the prognostic impact of lesion complexity on long-term outcomes of BVS. Copyright (c) 2021, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).
引用
收藏
页码:1458 / 1465
页数:8
相关论文
共 22 条
  • [1] Short- and Long-Term Outcomes With Drug-Eluting and Bare-Metal Coronary Stents A Mixed-Treatment Comparison Analysis of 117 762 Patient-Years of Follow-Up From Randomized Trials
    Bangalore, Sripal
    Kumar, Sunil
    Fusaro, Mario
    Amoroso, Nicholas
    Attubato, Michael J.
    Feit, Frederick
    Bhatt, Deepak L.
    Slater, James
    [J]. CIRCULATION, 2012, 125 (23) : 2873 - +
  • [2] Hybrid-stenting with metallic and bioresorbable drug-eluting stents 2-year clinical outcomes in KUM ABSORB registry
    Baquet, Moritz
    Grundmann, David
    Schmidt, Wolfgang
    Thienel, Manuela
    Jochheim, David
    Tesche, Christian
    Theiss, Hans Diogenes
    Brunner, Stefan
    Massberg, Steffen
    Mehilli, Julinda
    [J]. CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2019, 93 (01) : 71 - 78
  • [3] Clinical end points in coronary stent trials - A case for standardized definitions
    Cutlip, Donald E.
    Windecker, Stephan
    Mehran, Roxana
    Boam, Ashley
    Cohen, David J.
    van Es, Gerrit-Anne
    Steg, P. Gabriel
    Morel, Marie-angele
    Mauri, Laura
    Vranckx, Pascal
    McFadden, Eugene
    Lansky, Alexandra
    Hamon, Martial
    Krucoff, Mitchell W.
    Serruys, Patrick W.
    [J]. CIRCULATION, 2007, 115 (17) : 2344 - 2351
  • [4] Di Mario Carlo, 2007, EuroIntervention, V3, P30
  • [5] CORONARY MORPHOLOGICAL AND CLINICAL DETERMINANTS OF PROCEDURAL OUTCOME WITH ANGIOPLASTY FOR MULTIVESSEL CORONARY-DISEASE - IMPLICATIONS FOR PATIENT SELECTION
    ELLIS, SG
    VANDORMAEL, MG
    COWLEY, MJ
    DISCIASCIO, G
    DELIGONUL, U
    TOPOL, EJ
    BULLE, TM
    [J]. CIRCULATION, 1990, 82 (04) : 1193 - 1202
  • [6] Felix CM, 2016, J AM COLL CARDIOL IN, V9, P1652
  • [7] Mid- to long-term outcome of patients treated with everolimus-eluting bioresorbable vascular scaffolds: Data of the BVS registry Gottingen predominantly from ACS patients
    Hellenkamp, Kristian
    Becker, Alexander
    Gabriel, Yannick D.
    Hasenfuss, Gerd
    Huenlich, Mark
    Jacobshagen, Claudius
    Schillinger, Wolfgang
    Schroeter, Marco R.
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 234 : 58 - 63
  • [8] Bioresorbable vascular scaffold implantation for the treatment of coronary in-stent restenosis: Results from a multicenter Italian experience
    Moscarella, Elisabetta
    Varricchio, Attilio
    Stabile, Eugenio
    Latib, Azeem
    Ielasi, Alfonso
    Tespili, Maurizio
    Cortese, Bernardo
    Calabro, Paolo
    Granata, Francesco
    Panoulas, Vasileios F.
    Franzone, Anna
    Trimarco, Bruno
    Bonzani, Giulio
    Esposito, Giovanni
    Colombo, Antonio
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 199 : 366 - 372
  • [9] Bioresorbable vascular scaffold use for coronary bifurcation lesions: A substudy from GHOST EU registry
    Naganuma, Toru
    Colombo, Antonio
    Lesiak, Maciej
    Capodanno, Davide
    Gori, Tommaso
    Nef, Holger
    Caramanno, Giuseppe
    Naber, Christoph
    Di Mario, Carlo
    Ruparelia, Neil
    Capranzano, Piera
    Wiebe, Jens
    Araszkiewicz, Aleksander
    Geraci, Salvatore
    Kawamoto, Hiroyoshi
    Pyxaras, Stelios
    Mattesini, Alessio
    Muenzel, Thomas
    Tamburino, Corrado
    Latib, Azeem
    [J]. CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2017, 89 (01) : 47 - 56
  • [10] Bioresorbable Scaffold The Advent of a New Era in Percutaneous Coronary and Peripheral Revascularization?
    Onuma, Yosinobu
    Serruys, Patrick W.
    [J]. CIRCULATION, 2011, 123 (07) : 779 - 797